RxDoctor Payments Data

Mary Anderson

Acute Care · Baltimore, MDNPI 1225418221

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $899, 3.7 times the $242 reported in 2022.

$1,856in general payments, 2019–2025

Across 22 payments — averaging $84.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$440
  • W. L. Gore & Associates, Inc.$251
  • Tactile Systems Technology Inc$153
  • Takeda Pharmaceuticals U.S.A., Inc.$142
  • Johnson & Johnson$131
  • Seagen Inc.$120
  • plus $619 from 8 others

What the payments were for

  • Food & beverage$1,856100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,856 in reported general payments places this provider in the 85th percentile of 502 acute care providers in Maryland.

See all acute care providers in Maryland

Medicare billing

Part B allowed, 2024
$42,393
Medicare patients
138
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Valganciclovir Hcl18$32,141
Atovaquone33$23,642
LokelmaSodium Zirconium Cyclosilicate13$15,941
Tacrolimus91$14,909
Sirolimus23$10,278
ZarxioFilgrastim-Sndz14$8,485
Mycophenolate Mofetil17$4,059
ValacyclovirValacyclovir Hcl23$2,830
Azithromycin131$2,795
Pantoprazole Sodium78$1,072
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim63$508
Prednisone64$439
Pravastatin Sodium18$410
Ondansetron OdtOndansetron12$338
Albuterol Sulfate HfaAlbuterol Sulfate13$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$440$15,94113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 502 acute care providers in Maryland.

Other acute care in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →